Saeed Mohammadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saeed Mohammadi has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
Ardeshir Ghavamzadeh
Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
25 shared publications- Mohsen Nikbakht
Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
17 shared publications Kamran Alimoghaddam
Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran, Iran
15 shared publicationsMohsen Nikbakht
Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
12 shared publicationsAshraf Malek Mohammadi
Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
11 shared publications- Amir Hossein Norooznezhad
Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
10 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published byĀ Springer NatureĀ inĀ Cancer Nanotechnology
The role of platelet-derived microparticles in the progression of acute myeloid leukemia and their application in cancer nanotechnology
- 4 November 2026
- Published byĀ Springer NatureĀ inĀ Cancer Nanotechnology
Open AccessThe role of platelet-derived microparticles in the progression of acute myeloid leukemia and their application in cancer nanotechnology
- Open Access
- 30 September 2026
- Published byĀ Springer NatureĀ inĀ Stem Cell Research & Therapy
Butyrate in the epigenetic regulation of regulatory T cells: linking the microbiomeāimmune axis to gastrointestinal acute graft-versus-host disease
- 30 September 2026
- Published byĀ Springer NatureĀ inĀ Stem Cell Research & Therapy
Open AccessButyrate in the epigenetic regulation of regulatory T cells: linking the microbiomeāimmune axis to gastrointestinal acute graft-versus-host disease
- Open Access
- 30 May 2026
- Published byĀ ElsevierĀ inĀ Hematology, Transfusion and Cell Therapy
- Vol.Ā 48 Ā (3) , 106475
Predictive factors for poor mobilization in autologous stem cell transplant: a multivariate model
- 30 May 2026
- Published byĀ ElsevierĀ inĀ Hematology, Transfusion and Cell Therapy
- Vol.Ā 48 Ā (3) , 106475
Open AccessPredictive factors for poor mobilization in autologous stem cell transplant: a multivariate model
- Open Access
- 2 April 2026
- Published byĀ Springer NatureĀ inĀ Experimental Hematology & Oncology
- Vol.Ā 15 Ā (1) , 40
Clinical and translational advances in regulatory T cell-based strategies in allogeneic hematopoietic stem cell transplantation: highlights from ASH 2025
Regulatory T cells (Tregs), winners of the 2025 Nobel Prize in Physiology or Medicine, emerged as an unsung giant of peripheral immune tolerance after allo
- 2 April 2026
- Published byĀ Springer NatureĀ inĀ Experimental Hematology & Oncology
- Vol.Ā 15 Ā (1) , 40
Open AccessClinical and translational advances in regulatory T cell-based strategies in allogeneic hematopoietic stem cell transplantation: highlights from ASH 2025
Regulatory T cells (Tregs), winners of the 2025 Nobel Prize in Physiology or Medicine, emerged as an unsung giant of peripheral immune tolerance after allo
- 18 November 2025
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 53 Ā (1) , 94
Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes
Philadelphia chromosomeāpositive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22). This type of leukemia represents a biologically and clinically distinct subset of ALL, known for its aggressive nature and comparatively poor prognosis among hematologic malignancies. Although the advent of tyrosine kinase inhibitors (TKIs) has converted the therapeutic view and fulfilled short-term outcomes, resistant responses remain limited, and disease relapse, often due to BCR::ABL1 kinase domain mutations or activation of alternative signaling pathways, continues to impede long-term success. Recent findings emphasizes the essential involvement of microRNAs in leukemogenesis, TKI resistance, and the advancement of Ph+ ALL. Importantly, miR-17ā¼92 cluster members (such as miR-17, miR-18a, miR-20a) can prompt apoptosis by direct suppression of BCL2 in BCR::ABL1 positive cells. Moreover, epigenetic silencing of miR-203 enhances BCR::ABL1 expression, further contributing to TKI resistance. These small regulatory RNAs consequently act for promising candidates both as therapeutic targets and as prognostic biomarkers, with the potential to fill treatment gaps that persist even in the TKI era.
- 18 November 2025
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 53 Ā (1) , 94
Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes
Philadelphia chromosomeāpositive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22). This type of leukemia represents a biologically and clinically distinct subset of ALL, known for its aggressive nature and comparatively poor prognosis among hematologic malignancies. Although the advent of tyrosine kinase inhibitors (TKIs) has converted the therapeutic view and fulfilled short-term outcomes, resistant responses remain limited, and disease relapse, often due to BCR::ABL1 kinase domain mutations or activation of alternative signaling pathways, continues to impede long-term success. Recent findings emphasizes the essential involvement of microRNAs in leukemogenesis, TKI resistance, and the advancement of Ph+ ALL. Importantly, miR-17ā¼92 cluster members (such as miR-17, miR-18a, miR-20a) can prompt apoptosis by direct suppression of BCL2 in BCR::ABL1 positive cells. Moreover, epigenetic silencing of miR-203 enhances BCR::ABL1 expression, further contributing to TKI resistance. These small regulatory RNAs consequently act for promising candidates both as therapeutic targets and as prognostic biomarkers, with the potential to fill treatment gaps that persist even in the TKI era.
- 28 February 2025
- Published byĀ Knowledge E DMCCĀ inĀ Iranian Journal of Allergy, Asthma and Immunology
- Vol.Ā 24 Ā (1) , 52-60
Establishing an HLA-Typed Plateletpheresis Donor Registry at the Iranian Blood Transfusion Organization
Administering human leukocyte antigen (HLA)-compatible platelets is a tactic for treating patients with poor responses to random platelet injections. HLA-matched platelet provision requires many donors with HLA-typed and organized information. This study, the first of its kind in Iran, aimed to develop a registry system of HLA-typed platelet donors to facilitate the provision of compatible platelets to patients, leveraging the diversity of HLA alleles across Iran's various provinces. This study involved the HLA-typing of 1850 plateletpheresis donors, who were also registered as unrelated stem cell donors, across all blood centers in Iran from 2015 to 2022. HLA-A and HLA-B genotyping was conducted at a low-resolution using polymerase chain reaction-sequence specific primers (PCR-SSP) and real-time PCR. Statistical analysis was performed to determine allelic genotypes and donor profiles. The majority of the donors were male (99.7%), with a mean age of 36 years. The high donor rate in Tehran indicates a larger pool of potential HLA-platelet donors due to a denser population and more donation facilities. The donors were recruited for HLA-compatible plateletpheresis. The frequency of HLA-AB alleles among donors was relatively consistent with those documented by Iranians. Our findings can be utilized to create a foundational HLA database. A registry system for HLA-typed platelet donors is crucial due to high HLA polymorphism and ethnic diversity. This system facilitates the rapid identification of compatible donors based on HLA typing. Additional inquiries are needed to expand the plateletpheresis registry and make a request-supply mechanism between the Iranian Blood Transfusion Organization and hospitals.
- 28 February 2025
- Published byĀ Knowledge E DMCCĀ inĀ Iranian Journal of Allergy, Asthma and Immunology
- Vol.Ā 24 Ā (1) , 52-60
Establishing an HLA-Typed Plateletpheresis Donor Registry at the Iranian Blood Transfusion Organization
Administering human leukocyte antigen (HLA)-compatible platelets is a tactic for treating patients with poor responses to random platelet injections. HLA-matched platelet provision requires many donors with HLA-typed and organized information. This study, the first of its kind in Iran, aimed to develop a registry system of HLA-typed platelet donors to facilitate the provision of compatible platelets to patients, leveraging the diversity of HLA alleles across Iran's various provinces. This study involved the HLA-typing of 1850 plateletpheresis donors, who were also registered as unrelated stem cell donors, across all blood centers in Iran from 2015 to 2022. HLA-A and HLA-B genotyping was conducted at a low-resolution using polymerase chain reaction-sequence specific primers (PCR-SSP) and real-time PCR. Statistical analysis was performed to determine allelic genotypes and donor profiles. The majority of the donors were male (99.7%), with a mean age of 36 years. The high donor rate in Tehran indicates a larger pool of potential HLA-platelet donors due to a denser population and more donation facilities. The donors were recruited for HLA-compatible plateletpheresis. The frequency of HLA-AB alleles among donors was relatively consistent with those documented by Iranians. Our findings can be utilized to create a foundational HLA database. A registry system for HLA-typed platelet donors is crucial due to high HLA polymorphism and ethnic diversity. This system facilitates the rapid identification of compatible donors based on HLA typing. Additional inquiries are needed to expand the plateletpheresis registry and make a request-supply mechanism between the Iranian Blood Transfusion Organization and hospitals.
- 25 November 2024
- Published byĀ Academic World ResearchĀ inĀ Razi Journal of Medical Sciences
- Vol.Ā 31 Ā (1) , 1-10
Monitoring the Performance of Blood Donation Centers during the Outbreak of the COVID-19 Disease
Background & Aims: The outbreak of coronavirus disease 2019 (COVID-19) has led to the alteration in hygienic conditions. Direct transmission of the respiratory droplet during speaking and coughing and reaching the droplet to the mucosa is the most common way of transmitting COVID-19. Also, hand contact with contaminated surfaces can ...
- 25 November 2024
- Published byĀ Academic World ResearchĀ inĀ Razi Journal of Medical Sciences
- Vol.Ā 31 Ā (1) , 1-10
Monitoring the Performance of Blood Donation Centers during the Outbreak of the COVID-19 Disease
Background & Aims: The outbreak of coronavirus disease 2019 (COVID-19) has led to the alteration in hygienic conditions. Direct transmission of the respiratory droplet during speaking and coughing and reaching the droplet to the mucosa is the most common way of transmitting COVID-19. Also, hand contact with contaminated surfaces can ...
- Open Access
- 31 May 2023
- Published byĀ National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)Ā inĀ Experimental Oncology
- Vol.Ā 42 Ā (3) , 188-191
Osteopontin siRNA does not confer resistance to toxic effects of parthenolide in Jurkat cells
Summary. Background: Osteopontin (OPN) plays a critical role in cell proliferation and drug resistance in cancer treatment and hematological malignancies. In T cell acute lymphoblastic leukemia, most initial therapies can induce remission while some patients then relapse and do not respond well to chemotherapy. The sesquiterpene lactone parthenolide (PTL) can induce apoptosis in a variety of cancer cell lines via inhibition of pro-inflammatory transcription factor nuclear factor kappa B and has anti-tumor activity in acute lymphoblastic leukemia treatment. Aim: To study the role of OPN in conferring in vitro resistance to PTL in Jurkat cells. Methods: Jurkat cells were cultured with 8ā20 μm PTL for 48 h. Transfection with OPN siRNA was provided. Apoptosis assays were performed with Annexin V-Alexa Fluor-488/PI. Quantitative real-time polymerase chain reaction was used to measure OPN gene expression using the 2-2-ĪĪCt method. Results: PTL has cytotoxic and apoptotic effect on Jurkat cells with IC50 values of 16.1 μm, and growth inhibition effect of PTL does not differ significantly in combination with OPN-siRNA. OPN gene expression is not affected by PTL. Conclusions: Parthenolide induces apoptosis in Jurkat cells, but inhibition of osteopontin gene expression with siRNA does not reduce apoptotic effect of parthenolide.
- 31 May 2023
- Published byĀ National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)Ā inĀ Experimental Oncology
- Vol.Ā 42 Ā (3) , 188-191
Open AccessOsteopontin siRNA does not confer resistance to toxic effects of parthenolide in Jurkat cells
Summary. Background: Osteopontin (OPN) plays a critical role in cell proliferation and drug resistance in cancer treatment and hematological malignancies. In T cell acute lymphoblastic leukemia, most initial therapies can induce remission while some patients then relapse and do not respond well to chemotherapy. The sesquiterpene lactone parthenolide (PTL) can induce apoptosis in a variety of cancer cell lines via inhibition of pro-inflammatory transcription factor nuclear factor kappa B and has anti-tumor activity in acute lymphoblastic leukemia treatment. Aim: To study the role of OPN in conferring in vitro resistance to PTL in Jurkat cells. Methods: Jurkat cells were cultured with 8ā20 μm PTL for 48 h. Transfection with OPN siRNA was provided. Apoptosis assays were performed with Annexin V-Alexa Fluor-488/PI. Quantitative real-time polymerase chain reaction was used to measure OPN gene expression using the 2-2-ĪĪCt method. Results: PTL has cytotoxic and apoptotic effect on Jurkat cells with IC50 values of 16.1 μm, and growth inhibition effect of PTL does not differ significantly in combination with OPN-siRNA. OPN gene expression is not affected by PTL. Conclusions: Parthenolide induces apoptosis in Jurkat cells, but inhibition of osteopontin gene expression with siRNA does not reduce apoptotic effect of parthenolide.
- Open Access
- 4 April 2023
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 479 Ā (1) , 183-184
Correction: Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
- 4 April 2023
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 479 Ā (1) , 183-184
Open AccessCorrection: Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
- 18 February 2023
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 478 Ā (11) , 2435-2444
Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
Vimentin is a main type 3 intermediate filament protein. It seems that abnormal expression of vimentin is contributed to the appearance of the aggressive feature of cancer cells. So that it has been reported that malignancy and epithelialāmesenchymal transition in solid tumors, and poor clinical outcomes in patients with lymphocytic leukemia and acute myelocytic leukemia have been associated with the high expression of vimentin. Vimentin is a non-caspase substrate of caspase-9 although its cleavage by caspase-9 in biological processes has not been reported. In the present study, we sought to understand whether vimentin cleavage mediated by caspase-9 could reverse the malignancy in leukemic cells. Herein, to address the issue, we investigated vimentin changes in differentiation and took advantage of the inducible caspase-9 (iC9)/AP1903 system in human leukemic NB4 cells. Following the transfection and treatment of the cells using the iC9/AP1903 system, vimentin expression, cleavage, and subsequently, the cell invasion and the relevant markers such as CD44 and MMP-9 were evaluated. Our results revealed the downregulation and cleavage of vimentin which attenuates the malignant phenotype of the NB4 cells. Considering the favorable effect of this strategy in keeping down the malignant features of the leukemic cells, the effect of the iC9/AP1903 system in combination with all-trans-retinoic acid (ATRA) treatment was evaluated. The obtained data prove that iC9/AP1903 significantly makes the leukemic cells more sensitive to ATRA.
- 18 February 2023
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 478 Ā (11) , 2435-2444
Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
Vimentin is a main type 3 intermediate filament protein. It seems that abnormal expression of vimentin is contributed to the appearance of the aggressive feature of cancer cells. So that it has been reported that malignancy and epithelialāmesenchymal transition in solid tumors, and poor clinical outcomes in patients with lymphocytic leukemia and acute myelocytic leukemia have been associated with the high expression of vimentin. Vimentin is a non-caspase substrate of caspase-9 although its cleavage by caspase-9 in biological processes has not been reported. In the present study, we sought to understand whether vimentin cleavage mediated by caspase-9 could reverse the malignancy in leukemic cells. Herein, to address the issue, we investigated vimentin changes in differentiation and took advantage of the inducible caspase-9 (iC9)/AP1903 system in human leukemic NB4 cells. Following the transfection and treatment of the cells using the iC9/AP1903 system, vimentin expression, cleavage, and subsequently, the cell invasion and the relevant markers such as CD44 and MMP-9 were evaluated. Our results revealed the downregulation and cleavage of vimentin which attenuates the malignant phenotype of the NB4 cells. Considering the favorable effect of this strategy in keeping down the malignant features of the leukemic cells, the effect of the iC9/AP1903 system in combination with all-trans-retinoic acid (ATRA) treatment was evaluated. The obtained data prove that iC9/AP1903 significantly makes the leukemic cells more sensitive to ATRA.